StreetInsider.com News Articles

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans

Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease

A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients

NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients

I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

Tue, 05 May 2026 08:00:00 -0400

New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans
Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral, once-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease
A well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000 mg doses versus placebo to evaluate clinical remission and target engagement in ulcerative colitis patients
NIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically validated to provide clinical remission in both ulcerative colitis and Crohn’s disease patients
I&I oral therapeutic platform provides enhanced

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Tue, 24 Mar 2026 08:00:00 -0400

Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models
Newly discovered mechanisms in phagocytes and epithelial cells in combination with the well-established functional enhancement of Tregs provide LANCL2-mediated protection from inflammatory, autoimmune and neurodegenerative diseases
First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints and validated LANCL2 target engagement using transcriptional signature in blood
Phase 2-ready NIM-1324 is a de-risked, safe and well-tolerated, oral, once‑daily, small molecule LANCL2 therapeutic with ulcerative colitis as lead indication and key follow-on indications including Crohn’s disease, lupus, rheumatoid arthritis